Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

NCT02998047 is registered in ClinicalTrials.gov with Actinium Pharmaceuticals as lead sponsor.

NCT NCT02998047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02998047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
Lead sponsor
Actinium Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2016
Completion date
May 31, 2020
Enrollment
2 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma